{
  "id": 3535293,
  "title": "Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal",
  "url": "https://urgent.news/2026/08/26/biohaven-trades-cash-for-upside-with-795m-epilepsy-drug-deal",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-26T15:17:41.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/biohaven-sk-opakalim-epilepsy-drug-deal/828799/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}